Study shows Omicron sublineage BQ.1.1 is resistant to all monoclonal antibodies.

Omicron sublineage BQ.1.1 resistance to monoclonal antibodies – The Lancet Infectious Diseases

Commentaries: 

New Omicron subvariant BQ.1.1 resistant to all therapeutic antibodies, study finds – Deutsches Primatenzentrum (DPZ)/German Primate Center

Omicron variant BQ.1.1 found to be resistant to all monoclonal antibody treatments – MedicalXpress

Related: BQ.1 and BQ.1.1 are now the dominant COVID variants. What does that mean? – MedicalXpress

Commentary on Twitter

The BQ.1.1 variant, as compared with many of the other new variants, is resistant to all clinically used monoclonal antibodies.
BQ.1/BQ.1.1 are now the dominant variants in the United Stateshttps://t.co/PCFPSGF2uy @TheLancetInfDis pic.twitter.com/dHucxoGokC

— Eric Topol (@EricTopol) November 19, 2022